NCT01631903View on ClinicalTrials.gov

Extension of Study ZPV-200

PHASE2CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Uterine Fibroids

Interventions

DRUG

telepristone acetate 12 mg

12 mg, vaginal capsule, once daily for 4 months

DRUG

telepristone acetate 3 mg

3 mg, vaginal capsule, once daily for 3 months

DRUG

telepristone acetate 6 mg

6 mg, vaginal capsule, once daily for 3 months

DRUG

telepristone acetate 12 mg

12 mg, vaginal capsule, once daily, for 3 months

DRUG

telepristone acetate 24 mg

24 mg, vaginal capsule, once daily for 4 months

Trial Locations (2)

33169

Miami Gardens

77030

Houston

All Listed Sponsors

lead

Repros Therapeutics Inc.

INDUSTRY

NCT01631903 - Extension of Study ZPV-200 | Biotech Hunter | Biotech Hunter